- NIH Distinguished Investigator, Immunopathogenesis Section
Dr. Holland received his M.D. from the Johns Hopkins University School of Medicine in 1983, where he stayed as a resident in internal medicine, assistant chief of service in medicine, and fellow in infectious diseases. He came to the National Institutes of Health in 1989 as a National Research Council fellow in the Laboratory of Molecular Microbiology, working on transcriptional regulation of HIV. In 1991, Dr. Holland joined the Laboratory of Host Defenses, shifting his research to the host side, with a focus on phagocyte defects and their associated infections. His work centered on the pathogenesis and management of chronic granulomatous disease, as well as other congenital immune defects affecting phagocytes, including those predisposing to mycobacterial diseases. In 2004, he became chief of LCID.
- (2020). A Panoply of Rheumatological Manifestations in Patients with GATA2 Deficiency. Scientific Reports.
- (2019). IL-10 signaling in dendritic cells controls IL-1 beta-mediated IFN gamma secretion by human CD4(+) T cells: relevance to inflammatory bowel disease. Mucosal Immunology. 12(5), 1201-1211.
- (2020). Autoantibodies against type I IFNs in patients with life-threatening COVID-19. SCIENCE. 370(6515), 423-+.
- (2020). Everything a general paediatrician needs to know about primary immunodeficiencies. JOURNAL OF PAEDIATRICS AND CHILD HEALTH.
- (2020). Nocardiosis Associated with Primary Immunodeficiencies (Nocar-DIP): an International Retrospective Study and Literature Review. JOURNAL OF CLINICAL IMMUNOLOGY. 40(8), 1144-1155.
- (2020). Successful Matched Related Bone Marrow Transplantation in a Patient with Autosomal Dominant Interferon Gamma Receptor 1 Deficiency. JOURNAL OF CLINICAL IMMUNOLOGY. 40(7), 1045-1047.